By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Global Blood Therapeutics 

400 E. Jamie Court
Suite 101
South San Francisco  California  94080  U.S.A.
Phone: 650-741-7700 Fax: n/a


SEARCH JOBS

Global Blood Therapeutics is developing novel, orally-available therapeutics designed to change the treatment paradigm for chronic blood diseases. The Company is addressing severe, non-malignant blood-based diseases for which there are currently no effective cures and only extremely limited therapeutic options.

The current standard of care treats the symptoms during acute episodes; however, the underlying pathology of the disease causes progressive damage to the body. Global Blood Therapeutics is focused on the critical need for therapeutics that address the causes of blood diseases, not just the symptoms.

Global Blood Therapeutics’ extensive drug discovery capabilities — combining world-class medicinal chemistry with deep expertise in blood biology — are driving its product pipeline of mechanism-based therapeutics.

The Company has built a pipeline of preclinical programs focused on several blood diseases. Its lead program is in sickle cell disease, a global health challenge with very limited treatment options and none that address the underlying cause of the disease. The Company’s pipeline also includes a novel therapeutic for hereditary angioedema.

Global Blood Therapeutics is a private Company led by an experienced management team with a track record of four successful drug approvals and more than 30 investigational new drug applications. Backed by Third Rock Ventures, the Company was founded in 2012 with a $40.7 million Series A financing.


Key Statistics


Email: info@globalbloodtx.com
Ownership: Public

Web Site: Global Blood Therapeutics
Employees: n/a
Symbol: GBT
 



Industry
Biotechnology






Company News
Chengdu's HitGen To Collaborate With Global Blood Therapeutics (GBT) 1/11/2016 12:03:46 PM
Global Blood Therapeutics (GBT) Announces Positive Phase 1/2 Data Supporting Development Of GBT440 As A Potentially Disease-Modifying Therapy For Sickle Cell Disease 12/7/2015 10:31:25 AM
Global Blood Therapeutics (GBT) Announces Upcoming Investor Webcasts Including Event To Highlight GBT440 Data In Sickle Cell Disease At American Society of Hematology 11/30/2015 8:16:28 AM
Global Blood Therapeutics (GBT) Reports Recent Business Progress And Third Quarter 2015 Financial Results 11/12/2015 10:59:43 AM
Global Blood Therapeutics (GBT) Announces GBT440 Receives FDA Fast Track Designation For Sickle Cell Disease 10/12/2015 10:16:17 AM
Global Blood Therapeutics (GBT) Appoints Philip A. Pizzo, M.D. To Board Of Directors 9/24/2015 8:16:28 AM
Global Blood Therapeutics (GBT) Announces Participation At Three September Conferences 9/3/2015 7:30:17 AM
Global Blood Therapeutics (GBT) Announces Closing Of Initial Public Offering And Exercise Of Over-Allotment Option 8/18/2015 11:40:48 AM
Global Blood Therapeutics (GBT) Announces Pricing Of Initial Public Offering 8/12/2015 10:16:49 AM
Bay Area's Global Blood Therapeutics, Aimmune Jump on the IPO Wagon Seeking $115 Million Each 7/10/2015 6:18:27 AM
123
//-->